Impact of eravacycline on fibrinogen
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Emily Stevenson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Fibrinogen, Anti-Bacterial Agents, Afibrinogenemia, Tetracyclines. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objectives
While tigecycline has been associated with hypofibrinogenaemia, limited data with eravacycline suggest this may also occur with this agent. However, the incidence and clinical significance of this finding are not well defined.
Methods
This is a retrospective cohort study of hospitalized adults who received at least two doses of eravacycline between 1 August 2018 and 1 October 2024 and had two or more fibrinogen levels monitored while on therapy. The primary outcome was ≥50% reduction in fibrinogen while on eravacycline. Secondary outcomes included ≥25% reduction in fibrinogen, time to 50% fibrinogen reduction, development of hypofibrinogenemia (<200 mg/dL) and bleeding events.
Results
Thirty-nine patients were included with 17 (44%) being solid organ transplant recipients and 11 (28%) patients not considered to be immunocompromised. Eravacycline was primarily used to treat nontuberculosis mycobacterial infections (82%). The median (IQR) duration of eravacycline therapy was 12 (8–22) days. Thirty-three per cent of patients met the primary outcome of ≥50% decrease in fibrinogen with a median (IQR) time to 50% decrease in fibrinogen of 10 (8–11) days. A substantially higher number, 79%, experienced ≥25% reduction in fibrinogen. Hypofibrinogenaemia developed in 18 (49%) patients. A total of four (10%) patients experienced minor bleeding events.
Discussion
A majority of eravacycline-treated patients experienced at least a 25% decrease in fibrinogen levels. Although the decreased fibrinogen levels did not result in major clinically significant bleeding, fibrinogen levels should be monitored at baseline and at least weekly. Patients should also be monitored for any signs and symptoms of bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
- Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
ORCID-Profile: David Van Duin, Brent Footer
Zitieren
APA
Stevenson, E., Ponder, M., Daniels, L., Jones, T., Bartelt, L., Van Duin, D., & Footer, B. (2026). Impact of eravacycline on fibrinogen. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag030
Vancouver
Stevenson E, Ponder M, Daniels L, Jones T, Bartelt L, Van Duin D, et al. Impact of eravacycline on fibrinogen. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag030
BibTeX
@article{Stevenson2026,
author = {Stevenson, Emily and Ponder, Madison and Daniels, Lindsay and Jones, Travis and Bartelt, Luther and Van Duin, David and Footer, Brent},
title = {Impact of eravacycline on fibrinogen},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag030}
}
EUVIMED